Items 11 to 16 of 16 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tyrene CR4 | 1110670-40-0 | sc-296677 sc-296677A | 5 mg 50 mg | $101.00 $754.00 | ||
Tyrene CR4 exhibits a distinctive affinity for the Bcr protein, characterized by its ability to form robust π-π stacking interactions and electrostatic contacts. This compound induces a significant alteration in Bcr's conformation, impacting its engagement with various signaling partners. The kinetics of its interaction suggest a rapid initial binding followed by a slower, more stable association, allowing for prolonged modulation of Bcr's functional dynamics. Its unique structural attributes facilitate targeted disruption of key protein interactions, influencing cellular signaling pathways. | ||||||
Bcr-abl Inhibitor | 778270-11-4 | sc-203836 | 5 mg | $149.00 | 1 | |
Bcr-abl Inhibitor demonstrates a remarkable specificity for the Bcr-abl fusion protein, engaging through unique hydrogen bonding and hydrophobic interactions. This compound effectively stabilizes a particular conformation of Bcr-abl, which disrupts its downstream signaling cascades. The inhibitor's binding kinetics reveal a biphasic pattern, with an initial fast association followed by a gradual stabilization phase, enhancing its efficacy in modulating protein interactions and cellular responses. | ||||||
Elacridar-d4 | 143664-11-3 (unlabeled) | sc-218297 | 1 mg | $380.00 | ||
Elacridar-d4 exhibits a distinctive mechanism of action as a Bcr inhibitor, characterized by its ability to form strong π-π stacking interactions with aromatic residues in the target protein. This compound alters the conformational dynamics of Bcr, leading to a significant reduction in its activity. The reaction kinetics indicate a slow dissociation rate, allowing for prolonged engagement with the target, which enhances its overall impact on cellular pathways and protein interactions. | ||||||
Bafetinib | 859212-16-1 | sc-503249 | 1 mg | $250.00 | 1 | |
Bafetinib inhibits both BCR-ABL and Lyn tyrosine kinases, potentially suppressing the activity of c-Abl. | ||||||
DCC-2036 | 1020172-07-9 | sc-364482 sc-364482A | 10 mg 50 mg | $480.00 $1455.00 | ||
DCC-2036 (Rebastinib) is a switch control inhibitor of c-Abl, designed to overcome resistance mutations. | ||||||
KW 2449 | 1000669-72-6 | sc-364518 sc-364518A | 10 mg 50 mg | $180.00 $744.00 | ||
KW-2449 inhibits multiple kinases including c-Abl and has shown activity against BCR-ABL T315I mutant cells. | ||||||